Viveve Medical, Inc. (VIVE) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Viveve Medical, Inc. (VIVE) trades at $0.0002 with AI Score 48/100 (Grade C). Viveve Medical, Inc. specializes in developing and marketing medical devices for women's health, focusing on non-invasive treatments for conditions like vaginal introital laxity. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for VIVE: VIVE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VIVE against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VIVE: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Viveve Medical, Inc. (VIVE) Healthcare & Pipeline Overview
Viveve Medical, Inc. focuses on women's health, developing and marketing the Viveve System, a non-invasive radiofrequency treatment for vaginal introital laxity and sexual function. With a global presence through sales employees and distributors, the company operates in a competitive medical device landscape, addressing a growing demand for women's health solutions.
What Is the Investment Thesis for VIVE?
Viveve Medical operates in the women's health medical device market, focusing on non-invasive treatments. While the company has a global presence, its financial performance, indicated by a negative profit margin of -342.8% and a negative P/E ratio, raises concerns. The company's growth hinges on the successful commercialization and adoption of the Viveve System, as well as potential expansion into new markets and indications. Investors may want to evaluate the competitive landscape and the company's ability to achieve profitability and sustainable growth.
Based on FMP financials and quantitative analysis
VIVE Key Highlights
Viveve Medical operates in the medical device industry, focusing on women's health.
- The company's core product is the Viveve System, a radiofrequency-based treatment for vaginal introital laxity.
- Viveve Medical has a global presence, marketing its products in the United States, Canada, Asia Pacific, Europe, the Middle East, and Latin America.
- The company's gross margin is 9.6%.
- Viveve Medical's profit margin is -342.8%.
Who Are VIVE's Competitors?
VIVE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VIVE's Key Strengths?
Proprietary radiofrequency technology
- Global distribution network
- Focus on non-invasive treatments
- Established brand in the women's health market
What Are VIVE's Weaknesses?
Negative profit margin
- Limited product portfolio
- Dependence on the Viveve System
- Small market capitalization
What Could Drive VIVE Stock Higher?
Publication of new clinical data supporting the efficacy of the Viveve System.
- Expansion of the company's distribution network into new geographic markets.
- Development of new applications for the Viveve System's radiofrequency technology.
What Are the Key Risks for VIVE?
Financial-distress signal — its Altman Z-Score of -35.10 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
- Competition from alternative treatments for vaginal laxity.
- Regulatory hurdles and delays in obtaining approvals for new products.
- Reimbursement challenges from insurance providers.
- Negative profit margin and financial losses.
What Are the Growth Opportunities for VIVE?
- Expansion into New Geographic Markets: Viveve Medical has the opportunity to expand its market presence in underserved regions with a growing demand for women's health solutions. By strategically targeting specific countries and regions, Viveve can increase its revenue streams and establish a stronger global footprint. This expansion could involve partnerships with local distributors or the establishment of direct sales operations in key markets. Timeline: Ongoing.
- Development of New Applications for the Viveve System: The Viveve System's radiofrequency technology has the potential to be adapted for other women's health applications, such as the treatment of stress urinary incontinence or other pelvic floor disorders. By investing in research and development, Viveve can expand its product portfolio and address a broader range of patient needs. Timeline: 2-3 years.
- Strategic Partnerships and Acquisitions: Viveve Medical can pursue strategic partnerships or acquisitions to enhance its technology, expand its product offerings, or gain access to new markets. Collaborating with complementary companies or acquiring innovative technologies can accelerate Viveve's growth and strengthen its competitive position. Timeline: Ongoing.
- Increased Marketing and Awareness Campaigns: Viveve Medical can invest in targeted marketing campaigns to raise awareness of its products and educate healthcare providers and patients about the benefits of the Viveve System. By effectively communicating the clinical efficacy and safety of its technology, Viveve can drive adoption and increase sales. Timeline: Ongoing.
- Focus on Clinical Research and Data: Viveve Medical can strengthen its position by investing in clinical research to generate additional data supporting the efficacy and safety of the Viveve System. Publishing clinical studies in peer-reviewed journals and presenting data at medical conferences can enhance the credibility of the technology and attract more healthcare providers. Timeline: Ongoing.
What Are VIVE's Competitive Advantages?
- Patented Radiofrequency Technology: The Viveve System utilizes patented radiofrequency technology, providing a competitive advantage in the market for non-invasive vaginal rejuvenation treatments.
- Established Distribution Network: Viveve Medical has established a global distribution network, allowing it to reach customers in multiple countries and regions.
- Clinical Data and Efficacy: Clinical studies support the efficacy and safety of the Viveve System, providing a strong foundation for marketing and sales efforts.
What Does VIVE Do?
Founded in 2005 and headquartered in Englewood, Colorado, Viveve Medical, Inc. is a medical technology company dedicated to designing, developing, manufacturing, and marketing innovative medical devices for women's health. The company's primary focus is on non-invasive treatments for conditions such as vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. Viveve's flagship product, the Viveve System, utilizes patented radiofrequency technology to stimulate the body's natural collagen production process. The Viveve System comprises a radiofrequency generator, a reusable handpiece, and a disposable treatment tip, along with cryogen canisters and other consumable components. Viveve markets its products through a combination of direct sales employees and a network of distributors, reaching customers in the United States, Canada, the Asia Pacific region, Europe, the Middle East, and Latin America. The company continually seeks to expand its product offerings and geographic reach to address the evolving needs of women's health globally.
What Products and Services Does VIVE Offer?
- Designs medical devices for women's health.
- Develops non-invasive treatments for vaginal introital laxity.
- Manufactures the Viveve System, a radiofrequency-based treatment.
- Markets the Viveve System to healthcare providers.
- Offers solutions for sexual function and vaginal rejuvenation.
- Provides treatments for stress urinary incontinence.
How Does VIVE Make Money?
- Sells the Viveve System, including the radiofrequency generator and handpiece.
- Generates revenue from the sale of disposable treatment tips and cryogen canisters.
- Markets products through direct sales employees and distributors.
- Provides training and support to healthcare providers using the Viveve System.
What Industry Does VIVE Operate In?
Viveve Medical operates within the medical device industry, specifically targeting the women's health segment. This market is characterized by increasing demand for non-invasive and minimally invasive procedures. The competitive landscape includes companies offering alternative treatments for vaginal laxity and related conditions. Viveve's success depends on its ability to differentiate its technology, demonstrate clinical efficacy, and effectively market its products to healthcare providers and patients.
Who Are VIVE's Key Customers?
- Gynecologists and other women's health specialists.
- Medical spas and aesthetic clinics.
- Hospitals and outpatient surgical centers.
- Patients seeking non-invasive treatments for vaginal laxity and related conditions.
Company Profile
Viveve Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Englewood, US. The company is led by CEO Scott D. Durbin. VIVE has traded publicly since 1992.
Financial Health
Viveve Medical, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -35.10 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -85.0%, showing how much profit it generates from its asset base. A current ratio of 4.91 indicates the company holds enough short-term assets to cover its near-term obligations.
VIVE Valuation & Market Position
Relative to its peer group, VIVE's quantitative score of 48/100 is below the peer average of 65/100.
Earnings Track Record
Viveve Medical, Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 3.1% below estimates on average.
VIVE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary radiofrequency technology
- Global distribution network
- Focus on non-invasive treatments
- Established brand in the women's health market
Bear Case
- Negative profit margin
- Limited product portfolio
- Dependence on the Viveve System
- Small market capitalization
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
VIVE Latest News
No recent news available for VIVE.
VIVE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VIVE.
Price Targets
Wall Street price target analysis for VIVE.
VIVE MoonshotScore
What does this score mean?
The MoonshotScore rates VIVE 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Martin Kerber
CEO
Martin Kerber serves as the CEO of Viveve Medical, Inc. His background includes experience in managing and leading teams within the medical device industry. He is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership is focused on driving growth and innovation within the organization.
Track Record: Under Martin Kerber's leadership, Viveve Medical has focused on expanding its market presence and advancing its product pipeline. He has overseen the company's efforts to commercialize the Viveve System and explore new applications for its radiofrequency technology. His strategic decisions aim to improve the company's financial performance and enhance shareholder value.
VIVE OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Viveve Medical may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The availability of financial information for Viveve Medical may be limited due to its OTC listing.
- Lower Liquidity: Trading volume may be lower compared to stocks listed on major exchanges, potentially leading to wider bid-ask spreads.
- Regulatory Scrutiny: OTC-listed companies may face less regulatory oversight, increasing the risk of fraud or mismanagement.
- Delisting Risk: Viveve Medical could be delisted from the OTC market if it fails to meet certain requirements.
- Verify the company's financial statements and SEC filings.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Analyze the company's stock trading volume and liquidity.
- Check for any red flags or warning signs.
- Consult with a financial advisor.
- Established Business Operations: Viveve Medical has been in operation since 2005, indicating a level of business stability.
- Global Distribution Network: The company has a global distribution network, suggesting a broad market reach.
- Patented Technology: Viveve Medical's patented radiofrequency technology provides a competitive advantage.
- Focus on Women's Health: The company addresses a specific market need in the women's health sector.
VIVE Healthcare Stock FAQ
What does the AI Score mean for VIVE?
VIVE holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Viveve Medical, Inc. specializes in developing and marketing medical devices for women's health, focusing on non-invasive treatments for conditions like vaginal introital laxity. The company's core …
What does Viveve Medical, Inc. do?
Viveve Medical, Inc. is a medical technology company that designs, develops, manufactures, and markets medical devices for women's health. Its primary product is the Viveve System, which utilizes radiofrequency technology to provide non-invasive treatments for conditions such as vaginal introital laxity, sexual function, and stress urinary incontinence. The company markets its products globally through a combination of direct sales and distribution partners, targeting gynecologists, medical spas, and other healthcare providers.
What do analysts say about VIVE stock?
Currently, there is no readily available analyst consensus on Viveve Medical (VIVE) stock, potentially due to its OTC listing and smaller market capitalization. Investors should conduct their own thorough research and consider factors such as the company's financial performance, growth prospects, and competitive landscape. Given the negative profit margin and limited analyst coverage, caution and due diligence are advised.
What are the main risks for VIVE?
Viveve Medical faces several risks, including competition from established medical device companies and alternative treatments for vaginal laxity. Regulatory hurdles and the need for clinical data to support product efficacy also pose challenges. Additionally, the company's financial performance, characterized by a negative profit margin, raises concerns about its ability to achieve profitability and sustainable growth. The fact that it is an OTC stock also adds risk.
What are the key factors to evaluate for VIVE?
Viveve Medical, Inc. (VIVE) holds an AI score of 48/100 (low). Viveve Medical operates in the women's health medical device market, focusing on non-invasive treatments. Not financial advice.
How frequently does VIVE data refresh on this page?
VIVE's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VIVE's recent stock price performance?
Viveve Medical, Inc. (VIVE) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary radiofrequency technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VIVE overvalued or undervalued right now?
Viveve Medical, Inc. (VIVE) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VIVE before investing?
Before investing in Viveve Medical, Inc. (VIVE), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recently available information.
- The analysis is based on publicly available information and management's statements.